Skip to content
ChickenStockChickenStock
ResearchIONS
Ionis Pharmaceuticals logo

Ionis Pharmaceuticals (IONS) stock

NASDAQ

$29.05+6.37%(+1.74)

As of the Nov 13, 2026 close (U.S. Eastern)

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-8.84x

Net loss — not comparable

P/B

12.28x

P/S

5.04x

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Revenue increased 54.8% from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 9, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

11 SEC filings
  • Hayden Michael RDirector · Nov 10, 2026Open-market purchase5,000 shares · $148K
    Avg. price $29.6427,000 shares held after
  • Devers Shannon L.EVP, Chief Human Resources Ofc · Oct 16, 2026Open-market sale1,357 shares · $59K
    Avg. price $43.538617,811 shares held after
  • Swayze EricEVP Research · Oct 16, 2026Open-market sale53 shares · $2K
    Avg. price $43.5389390 shares held after
  • Devers Shannon L.EVP, Chief Human Resources Ofc · Oct 15, 2026Option exercise2,820 shares · $0
    Avg. price $019,168 shares held after
  • Swayze EricEVP Research · Oct 15, 2026Option exercise125 shares · $0
    Avg. price $0443 shares held after
  • BENNETT C FRANKEVP, Chief Scientific Officer · Aug 31, 2026Other110 shares · $6K
    Avg. price $51.30660,128 shares held after
  • Monia Brett PChief Executive Officer · Aug 31, 2026Other98 shares · $5K
    Avg. price $51.306242,760 shares held after
  • O'NEIL PATRICK R.EVP CLO & General Counsel · Aug 31, 2026Other63 shares · $3K
    Avg. price $51.30659,205 shares held after
  • Birchler BrianEVP, Corp and Development Ops · Aug 31, 2026Other58 shares · $3K
    Avg. price $51.306102,883 shares held after
  • Hayden Michael RDirector · Jul 31, 2026Open-market purchase5,000 shares · $258K
    Avg. price $51.624,000 shares held after
  • Hayden Michael RDirector · Jul 30, 2026Open-market purchase15,000 shares · $801K
    Avg. price $53.3819,000 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Ionis Pharmaceuticals (IONS) stock information

NASDAQ

Ionis Pharmaceuticals (IONS) is listed on NASDAQ. Its market capitalization is about $4.8B. On trailing-twelve-month earnings the P/E ratio is -8.84, and the P/B ratio is 12.28. Return on equity is -138.8%. These figures are computed in-house from official filings and are reference information only.

Ionis Pharmaceuticals — frequently asked questions

What is the P/E ratio of Ionis Pharmaceuticals (IONS)?
On a trailing-twelve-month basis, IONS trades at a P/E ratio of -8.84. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Ionis Pharmaceuticals?
IONS has a market capitalization of about $4.8B. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.